sentiment_stocks Saturday, 09/12/20 02:52:30 PM Re: snoopycomic post# 306695 Post # of 385553 Here's the transcribed opening section where LP indicates that they are still expecting to give us top line in September. You'll note as well that she still indicates that they are expecting to unblind the results of the trial. Quote:Hello, my name is Linda Powers. I’m the CEO of Northwest Biotherapeutics. Our company is developing personalized immune therapies for cancer. Particularly brain cancer. We’re very pleased to be able to support ABTA’s Annual Meeting 2020, and we think ABTA’s work in the field is super important, super helpful for the whole field. I’d like to take about five minutes to just talk about three subjects that I think may be of interest to folks. Firstly, the key challenge for immune therapy is in trying to treat solid tumor cancers. Secondly, I’d like to describe a little bit about some of the key elements of the immune system, the human immune system, that offer a real opportunity for, we believe, powerful treatments for cancers. And thirdly, I’ll describe a little bit about our particular approach with our DCVax technology. I will flag, right from the beginning, we’re very excited because just in the next couple weeks, later this month of September, we will be expecting to unblind, unveil, and announce, finally, the results of our thirteen year long phase three trial of DCVax for glioblastoma brain cancer. And we think this study is going to be a major contribution to the field in terms of data, and we certainly hope to be able to bring a new treatment option to patients. So please stay tuned to see those clinical trial results in just a few weeks.